Geron Announces Conference Call for Top-Line Results from IMerge Phase 3

Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) will host a conference call on January 4, 2023, at 8:00 a.m. ET to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat for lower risk myelodysplastic syndromes (MDS). Investors can access the call via a live webcast on Geron’s website. Imetelstat is a first-in-class telomerase inhibitor aimed at treating hematologic malignancies. This trial represents a significant step in evaluating the drug's potential to impact patients' lives.

Positive

• Hosting a conference call to discuss top-line results indicates transparency and engagement with investors.
• Imetelstat is positioned as a first-in-class therapy, potentially establishing Geron as a leader in treating MDS.

Negative

• None.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat, the Company’s first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS) on January 4, 2023, at 8:00 a.m. ET.

A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL. Participants that are unable to register online can access the conference call via telephone by dialing domestically +1 (888) 330-2434 or internationally +1 (240) 789-2725, and then pressing # to reach an operator to be directed to the call.

About Geron

Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. The Company’s first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. Geron currently has a Phase 3 clinical trial underway evaluating imetelstat in each of: (i) lower risk myelodysplastic syndromes (LR MDS), and (ii) relapsed/refractory myelofibrosis (MF). To learn more, visit www.geron.com or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005168/en/

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

What is the IMerge Phase 3 clinical trial for Geron Corporation?

The IMerge Phase 3 clinical trial evaluates imetelstat, a telomerase inhibitor, for treating lower risk myelodysplastic syndromes (MDS).

When will the conference call regarding imetelstat results take place?

The conference call is scheduled for January 4, 2023, at 8:00 a.m. ET.

How can I access the conference call for Geron's IMerge trial results?

The call can be accessed via a live webcast on Geron's website or by telephone.

What is the significance of imetelstat in treating hematologic malignancies?

Imetelstat is a first-in-class telomerase inhibitor that may alter the underlying drivers of disease in patients with hematologic malignancies.